Loading...
Lung cancer incidence is five- to sixfold higher among patients with idiopathic pulmonary fibrosis (IPF) than among people without IPF. Antifibrotic medication, which was first approved for IPF in 2014, slows the rate of decline in pulmonary function and might lengthen survival. Mayo Clinic researchers retrospectively studied 3300 patients with IPF (diagnosed between 2005 and 2022) to determine if antifibrotic medication also lowers risk for lung cancer.
Patients who received antifibrotic therapy had lower likelihood of developing lung cancer (0.34 vs. 1.25 cases per 100 person-years).
The cumulative incidence of lung cancer during 10 years of follow-up was significantly lower for patients who received antifibrotics than for…